TherapeuticsDOSAGE AND SAFETY OF LONG-TERM SUPPRESSIVE ACYCLOVIR THERAPY FOR RECURRENT GENITAL HERPES
References (14)
- et al.
Prophylactic oral acyclovir in recurrent genital herpes
Lancet
(1984) - et al.
Intravenous acyclovir treatment for primary genital herpes
Lancet
(1982) - et al.
Oral acyclovir for episodic treatment of recurrent genital herpes
J Am Acad Dermatol
(1986) - et al.
Double-blind comparison of weekend and daily regimens of oral acyclovir for suppression of recurrent genital herpes
Antiviral Res
(1986) - et al.
A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection
N Engl J Med
(1994) - et al.
Suppression of frequently recurring genital herpes. A placebo controlled double blind trial of oral acyclovir
N Engl J Med
(1984)
There are more references available in the full text version of this article.
Cited by (106)
Antiviral Agents
2018, Principles and Practice of Pediatric Infectious DiseasesHerpes Simplex Virus
2014, Mandell, Douglas, and Bennett's Principles and Practice of Infectious DiseasesAntiviral agents for herpes simplex virus
2013, Advances in PharmacologyCitation Excerpt :From this study, it was concluded that both FCV (1000 mg twice for 1 day) and VACV (500 mg twice daily for 3 days) were equally effective in reducing the duration of the symptoms of genital herpes and both probably increased the likelihood that papules did not develop into lesions, with a trend in favor of FCV. Mindel et al. (1988) tested ACV at different doses (200–800 mg) for time to first recurrence in a 12-week trial. The number of doses/day was more important than the dose/day.
Antiviral Agents
2012, Principles and Practice of Pediatric Infectious Diseases, Fourth EditionANTIVIRAL AGENTS
2009, Feigin and Cherry's Textbook of Pediatric Infectious Diseases, Sixth EditionAntiviral therapies in children: Has their time arrived?
2005, Pediatric Clinics of North America
Copyright © 1988 Published by Elsevier Ltd.